CytoMed Therapeutics (GDTC) Short term Debt (2021 - 2022)
CytoMed Therapeutics (GDTC) recorded Short term Debt of $41,845 in Q2 2026.
Powered by 
Analysis
CytoMed Therapeutics (GDTC) Short term Debt (2021 - 2022) Analysis & Trends
At the end of FY2025, CytoMed Therapeutics reported Short term Debt of $40,847.
- Annual Short term Debt has a four-year compound annual growth rate of -63.5% (FY2021 to FY2025).
- Across earlier years, Short term Debt came in at $3.4 million in FY2022 (+47.2%) and $2.31 million in FY2021.
- The Q2 2026 figure is the highest quarterly Short term Debt since Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | CytoMed Therapeutics | 9.44 Mn | -158,924.18 | - |
API Access
CytoMed Therapeutics Short term Debt API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=short-term-debt&ticker=GDTC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "short-term-debt", "ticker": "GDTC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=short-term-debt&ticker=GDTC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();